Rheumatoid arthritis: The management of rheumatoid arthritis in adults
This is an extract from the guidance and may be misleading if read alone. The complete guidance is available at guidance.nice.org.uk/cg79
Important information about this guideline
This guidance updates and replaces the following technology appraisals:
-
'Guidance on the use of cyclo-oxygenase (Cox) II selective inhibitors, celecoxib, rofecoxib, meloxicam and etodolac for osteoarthritis and rheumatoid arthritis' (NICE technology appraisal guidance 27)
-
'Anakinra for rheumatoid arthritis' (NICE technology appraisal guidance 72)
Note that recommendations 1.4.4.2 – 1.4.4.5 are adapted from 'Osteoarthritis: the care and management of osteoarthritis in adults' (NICE clinical guideline 59). These recommendations form part of the update of the rheumatoid arthritis aspects of NICE technology appraisal guidance 27.
There has been a change to recommendation 1.4.4.3 in this guideline since publication. This web version contains the current wording of the recommendations. For information about the changes, see the web summary page for the guideline.